With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.93319-65-4,Pyridazin-3-ylmethanamine,as a common compound, the synthetic route is as follows.
The title compound is prepared according to General Procedure 13 described in Example 52, using 3-{[8-(1-methyl-1 -/-indol-6-yl)quinoxalin-6- yl]amino}pyridine-4-carboxylic acid (Intermediate 42, 80 mg; 0.20 mmol; 1 eq.), pyridazin-3-yl-methylamine (28 mg; 0.25 mmol; 1.25 eq.), EDC-HCI (69 mg; 0.35 mmol; 1.80 eq.), HOBt hydrate (55 mg; 0.35 mmol; 1.80 eq.), triethylamine (0.13 ml0.98 mmol; 5 eq.) and dioxane (5 ml_). Conditions: room temperature for 24 h. Purification by FCC (0% to 10% MeOH gradient in DCM) yields 3-{[8-(1-methyl- H-indol-6-yl)quinoxalin-6-yl]amino}-//- [(pyridazin-3-yl)methyl]pyridine-4-carboxamide (40 mg; 0.08 mmol; 41 %; yellow powder; HPLC purity: 97%).
The synthetic route of 93319-65-4 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; SELVITA S.A.; FABRITIUS, Charles-Henry Robert Yves; NOWAK, Mateusz Oktawian; WIKLIK, Katarzyna Anna; SABINIARZ, Aleksandra Barbara; BIE?, Marcin Dominik; BUDA, Anna Malgorzata; GUZIK, Pawel Szczepan; BIA?AS, Arkadiusz Kacper; PAWLIK, Henryk Edward; BOUTARD, Nicolas Felix Pierre; (439 pag.)WO2016/180537; (2016); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem